Under the collaboration, ArsenalBio will be responsible for discovering and building preclinical candidates against multiple targets, and Bristol Myers will have the option to obtain exclusive worldwide license to develop and commercialize preclinical candidates. Following the exercise of the option, Bristol Myers would be solely responsible for developing and commercializing the licensed candidates.

ArsenalBio will use its synthetic biology compositions to build programmable cell therapy product candidates, made of its PrimeR logic gates, CARchitecture derived gene expression controls, and CellFoundry mediated nonviral manufacturing process. Combined, these three components form circuit-modified T cells.

Under the agreement, Bristol Myers will make an upfront payment of $70 million to ArsenalBio. ArsenalBio will be eligible to receive additional payments associated with collaboration expansion, regulatory, and sales milestones, as well as potential royalties on sales of approved products. Bristol Myers will also make an investment in ArsenalBio for an undisclosed amount.

Regulatory Roundup: antibodies, immunotherapies, expanded flu treatment use
Welcome to this week's edition of Regulatory Roundup. This past week, several novel therapies for the treatment of rare diseases and cancers have received...

Insitro, Bristol Myers Squibb collaborate on novel treatments
Insitro has entered into a five-year agreement with Bristol Myers Squibb for the discovery and development of novel therapies for the treatment of amyotrophic...

Bristol Myers Squibb advances cancer immunotherapy in Europe
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb's nivolumab (Opdivo).

Bristol Myers Squibb licenses cell therapy candidate from Obsidian
Bristol Myers Squibb has exercised an option to an exclusive worldwide license to a cell therapy candidate based on Obsidian Therapeutics' cytoDrive technology.

Bristol Myers licenses immunotherapy from Dragonfly
Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.